Orforglipron

Name: Orforglipron | 2212020-52-3
Brand: US-CATO
SKU: S57C1830160_5_MG
Price: 19998.0 USD
Availability: OutOfStock

Cat. No S57C1830160_5_MG

Vendor: US-CATO

Product Information

Product Name

Orforglipron

Brand Name

US-CATO

Product Number

C1830160

CAS

2212020-52-3

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

137319706

IUPAC Name

3-(1S,2S)-1-5-(4S)-2,2-dimethyloxan-4-yl-2-(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl-4-methyl-6,7-dihydro-4H-pyrazolo4,3-cpyridine-5-carbonylindol-1-yl-2-methylcyclopropyl-4H-1,2,4-oxadiazol-5-one

InChI Key

USUWIEBBBWHKNI-KHIFEHGGSA-N

SMILES

CC@H1CC@1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)C@H5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7C@@H6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C

References Data Source From Pubchem

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Publication Name: The New England journal of medicine

Publication Date: 2025-09-18

DOI: 10.1056/nejmoa2505669

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes

Publication Name: Cardiovascular Diabetology

Publication Date: 2025-06-06

DOI: 10.1186/s12933-025-02781-x

The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron

Publication Name: Science Translational Medicine

Publication Date: 2024-12-18

DOI: 10.1126/scitranslmed.adp5765

Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials

Publication Name: Archives of Endocrinology and Metabolism

Publication Date: 2024-09-11

DOI: 10.20945/2359-4292-2023-0469

Binding sites and design strategies for small molecule GLP-1R agonists

Publication Name: European Journal of Medicinal Chemistry

Publication Date: 2024-09-05

DOI: 10.1016/j.ejmech.2024.116632

Orforglipron

Product Information

General Information

References Data Source From Pubchem

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes

The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron

Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials

Binding sites and design strategies for small molecule GLP-1R agonists

Orforglipron

Mycophenolate Mofetil EP Impurity H

Mycophenolate Mofetil

Flurbiprofen Impurity 21 (Mixture of Diastereomers)

Docetaxel Impurity 40

H-Met-Glu-OH

Fluticasone Impurity 106

Efavirenz Related Compound C

Cholecalciferol EP Impurity A

About Us

Popular Searches

Contact

#title#

Features
Availability:
Price
Options
Actions

Orforglipron

Product Information

General Information

References Data Source From Pubchem

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes

The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron

Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials

Binding sites and design strategies for small molecule GLP-1R agonists

Orforglipron

Related Product

Mycophenolate Mofetil EP Impurity H

Mycophenolate Mofetil

Flurbiprofen Impurity 21 (Mixture of Diastereomers)

Docetaxel Impurity 40

H-Met-Glu-OH

Fluticasone Impurity 106

Efavirenz Related Compound C

Cholecalciferol EP Impurity A

#title#

Login

Register